Pfizer, a publicly owned company headquartered in the US, was founded in 1849. The company employs approximately 100,900 people and specializes in pharmaceutical manufacturing.
Pfizer is quietly reshaping its pipeline with a burst of early-stage trial activity spanning obesity, oncology, and cardiovascular disease. Earlier on April 25, the company's stock price decline pushed its dividend yield to 6.3%, which management affirmed it plans to support. Also on April 25, new data presented at the Pediatric Academic indicated that maternal respiratory syncytial virus (RSV) vaccination and postnatal administration of nirsevimab were associated with reduced infection rates and disease severity among infants younger than six months. This followed an earlier announcement on April 25 that Pfizer, in partnership with Bristol Myers Squibb, is offering Eliquis directly to cash-paying patients on Mark Cuban's Cost Plus Drug Company platform to improve access and price transparency for the widely used branded blood thinner.
Subscribe for full access to Pfizer's products in full detail
Subscribe for full access to Pfizer's revenue in full detail
Subscribe for full access to Pfizer's products in full detail 
